BGP-15(BGP-15) - 药物靶点：HSP x PARP_在研适应症：2型糖尿病，杜氏肌营养不良症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

HSP x PARP

作用机制

HSP刺激剂(热休克蛋白刺激剂)、PARP抑制剂(聚腺苷二磷酸核糖聚合酶抑制剂)、胰岛素增敏剂

治疗领域

神经系统疾病遗传病与畸形内分泌与代谢疾病+ [2]

在研适应症

2型糖尿病杜氏肌营养不良症

非在研适应症

β-酮硫解酶缺乏症化疗引起的损伤新型冠状病毒感染+ [3]

原研机构

N-Gene

在研机构

N-Gene

非在研机构

N-Gene Research Laboratories, Inc.

Allos Therapeutics, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C14H22N4O2

InChIKeyMVLOQULXIYSERZ-UHFFFAOYSA-N

CAS号66611-38-9

查看全部结构式(2)

关联

4

项与 BGP-15 相关的临床试验

EUCTR2020-003005-61-HU / Unknown status临床2期

A phase 2 study on the clinical efficacy of adjuvant BGP-15 treatment additional to beta-blocker bisoprolol in patients with inappropriate sinus tachycardia

开始日期2020-09-30

申办/合作机构-

ACTRN12616000482460 / Withdrawn临床2期

An Exploratory Phase 2 Study to Determine Safety, Tolerability and Impact of BGP-15 on cardiac fibrosis and ventricular remodelling in patients with Non-Ischaemic Dilated Cardiomyopathy (NIDCM)

开始日期2016-06-06

申办/合作机构

Baker Heart & Diabetes Institute

NCT01069965 / Terminated临床2期

Randomized, Double-blind, Placebo-controlled, Parallel Group, Multiple Dose, Multicenter Study to Assess Safety & Efficacy of BGP-15 Administered Orally 1 or 2 Times Daily With Metformin & Sulfonylurea or Metformin in T2 Diabetic Patients

This is a safety and dose finding efficacy study to evaluate the effects of BGP-15 over the dose range of 100 mg/day to 400 mg/day. Doses are applied once or twice a day for 13 weeks as add-on therapy to the combination of metformin and sulfonylurea treatment or metformin alone in patients with Type 2 Diabetes Mellitus.

开始日期2010-10-01

申办/合作机构

N-Gene Research Laboratories, Inc.

[+6]

100 项与 BGP-15 相关的临床结果

登录后查看更多信息

100 项与 BGP-15 相关的转化医学

登录后查看更多信息

100 项与 BGP-15 相关的专利（医药）

登录后查看更多信息

76

项与 BGP-15 相关的文献（医药）

2024-08-01·Computers in Biology and Medicine

CAS3D: 3D quantitative morphometry on Second Harmonic Generation image volumes from single skeletal muscle fibers

Article

作者: Ritter, Paul ; Mnuskina, Sofia ; Schneidereit, Dominik ; Nübler, Stefanie ; Friedrich, Oliver ; Mühlberg, Alexander ; Kreiss, Lucas ; Bauer, Julian ; Larsson, Lars ; Schürmann, Sebastian ; Cacciani, Nicola

The CAS3D image processing method intuitively applies a combination of Fourier space and real space 3D analysis algorithms to volumetric images of single skeletal muscle fiber Myosin II Second Harmonic Generation (SHG) XYZ image data. Our developed tool automatically quantifies the myofibrillar orientation in muscle samples by determining the cosine angle sum of intensity gradients in 3D (CAS3D) while determining the mean sarcomere length (SL) and sample orientation. The expected CAS3D values could be reproduced from ideal artificial data sets. Applied random noise in artificial images lowers the detected CAS3D value, and for noise levels below 20%, the correlation can be approximated by a linear function with a slope of -0.006 CAS3D/noise%. The deviations in SL and orientation detection were determined on ideal and noisy artificial data sets and were statistically indistinguishable from 0 (null hypothesis t-test P > 0.1). The software was applied to a previously published data set of single skeletal muscle fiber volumetric SHG image data from a rat intensive care unit (ICU) model of ventilator-induced diaphragm dysfunction (VIDD) with treatment regimens involving the small anti-inflammatory molecules BGP-15, vamorolone, or prednisolone. Our method reliably reproduced the results of the previous work and improved the standard deviation of the cosine angle sum detection in all sample groups from a mean of 0.03 to 0.008. This improvement is achieved by applying analysis algorithms to the whole volumetric images in 3D in contrast to the previously common method of slice-wise XY analysis.

2024-08-01·Brain, Behavior, and Immunity

Response to comment on: BGP-15 alleviates LPS-induced depression-like behavior by promoting mitophagy

Letter

作者: Liu, Qian ; Liu, Gong-Ping

A review.In this investigation, we discovered that BGP-15 can improve depressive-like behaviors (DLB) in mice by promoting PINK1/Parkin-dependent mitophagy, but the mechanism is not clear.In vitro studies revealed that BGP-15 interacts with mitochondrial proteins or lipids.It is hypothesized that the mechanism by which BGP-15 improves mitophagy may involve its mitochondrial targeting, warranting further investigation.

2024-08-01·Brain, Behavior, and Immunity

Commentary on the Article “BGP-15 alleviates LPS-induced depression-like behavior by promoting mitophagy”

Article

作者: Chen, Haiyang ; Ren, Lu ; Shi, Liuqing

A polemic in response to Liu et al., 2024 (Brain Behav. Immun. 119, 648-664)is given.Liu et al. described potential role of BGP-15 as a neuroprotective agent in enhancing mitophagy and suppressing the activation of the NLRP3 inflammasome offers fresh perspective for the treatment of depression.The author after a thorough anal. of the study raised few queries and suggestions as follows:.While the paper mentions that BGP-15 acts through the PINK1/Parkin-dependent mitophagy pathway, the specific mol. mechanisms by which BGP-15 influences this pathway are not elaborated. Could future research provide more details on the interaction between BGP-15 and proteins involved in mitophagy.Given that BGP-15 has shown good tolerability in other clin. trials, have the authors considered applying it to clin. studies involving patients with depression The outcomes of such studies could significantly impact clin. practice.The study utilized male mice, but it is well-documented that gender differences exist in the prevalence and presentation of depression. Will future studies consider including female mice to assess the impact of gender on the effects of BGP-15.Besides mitophagy and the NLRP3 inflammasome mentioned in the paper, are there other biomarkers or pathways that might be associated with the antidepressant effects of BGP-15.Author impressed by the depth and quality of this research and look forward to the authors' perspectives on the above issues and believe that further research and discussion will enable us to fully understand the potential of BGP-15 in the treatment of depression.

100 项与 BGP-15 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
窦性心动过速	临床3期	匈牙利	-	2020-09-30
胰岛素抵抗	临床3期	匈牙利	N-Gene Research Laboratories, Inc.	2006-04-04
2型糖尿病	临床2期	-	N-Gene	-
杜氏肌营养不良症	临床2期	-	N-Gene	-
β-酮硫解酶缺乏症	临床1期	匈牙利	N-Gene Research Laboratories, Inc.	2010-10-01
β-酮硫解酶缺乏症	临床1期	美国	N-Gene Research Laboratories, Inc.	2010-10-01
β-酮硫解酶缺乏症	临床1期	德国	N-Gene Research Laboratories, Inc.	2010-10-01
化疗引起的损伤	临床1期	匈牙利	N-Gene Research Laboratories, Inc.	-
再灌注损伤	临床1期	匈牙利	-	-
新型冠状病毒感染	药物发现	匈牙利	-	2021-03-26